The update became effective April 1, according to a June 10 news release.
The FDA-approved device has been shown to improve lung function and reduce breathlessness in patients with significant emphysema symptoms, the statement said.
Other payers covering the treatment include Aetna and Humana.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
